Mutations of CB1 T210 produce active and inactive receptor forms: Correlations with ligand affinity, receptor stability, and cellular localization

Biochemistry

Volumn 45, Issue 17, 2006, Pages 5606-5617

  D'Antona, Aaron M ^a   Ahn, Kwang H ^a   Kendall, Debra A ^a  

^a UNIVERSITY OF CONNECTICUT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOCHEMISTRY; CELLS; DISEASES; PROTEINS; THERMODYNAMIC STABILITY;

HUMAN CANNABINOID RECEPTOR 1; LIGAND AFFINITY; T210A RECEPTOR-GFP CHIMERA; WILD TYPE;

MUTAGENESIS;

ALANINE; CANNABINOID 1 RECEPTOR; CANNABINOID RECEPTOR AGONIST; G PROTEIN COUPLED RECEPTOR; GREEN FLUORESCENT PROTEIN; GUANINE NUCLEOTIDE BINDING PROTEIN; GUANOSINE 5' O (3 THIOTRIPHOSPHATE); ISOLEUCINE; RIMONABANT; THREONINE; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; ARACHIDONIC ACID DERIVATIVE; ARACHIDONYL 2 CHLOROETHYLAMIDE; ARACHIDONYL-2-CHLOROETHYLAMIDE; CYCLIC AMP; DEXANABINOL; DRUG DERIVATIVE; LIGAND; METHANANDAMIDE; MORPHOLINE DERIVATIVE; NAPHTHALENE DERIVATIVE; PIPERIDINE DERIVATIVE; PYRAZOLE DERIVATIVE; TETRAHYDROCANNABINOL;

AMINO ACID SUBSTITUTION; ARTICLE; CELL STRAIN HEK293; CELL SURFACE; CELLULAR DISTRIBUTION; CHIMERA; CONTROLLED STUDY; GENE EXPRESSION; GENE MUTATION; GENETIC CONSERVATION; HUMAN; HUMAN CELL; INTERNALIZATION; LIGAND BINDING; MOLECULAR STABILITY; MULTIGENE FAMILY; MUTAGENESIS; OBESITY; OBSESSION; PRIORITY JOURNAL; PROTEIN MOTIF; REGULATORY MECHANISM; THERMOSTABILITY; WILD TYPE; AMINO ACID SEQUENCE; CELL CULTURE; CYTOLOGY; DRUG ANTAGONISM; DRUG POTENTIATION; DRUG STABILITY; GENETICS; HEAT; KIDNEY; METABOLISM; MUTATION; PHYSIOLOGY;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ARACHIDONIC ACIDS; CELLS, CULTURED; CYCLIC AMP; DRUG STABILITY; GUANOSINE 5'-O-(3-THIOTRIPHOSPHATE); HEAT; HUMANS; KIDNEY; LIGANDS; MORPHOLINES; MUTATION; NAPHTHALENES; PIPERIDINES; PYRAZOLES; RECEPTOR, CANNABINOID, CB1; TETRAHYDROCANNABINOL; THREONINE;

EID: 33646363596     PISSN: 00062960     EISSN: None     Source Type: Journal    
DOI: 10.1021/bi060067k     Document Type: Article

References (71)

1. Palczewski, K., Kumasaka, T., Hori, T., Behnke, C. A., Motoshima, H., Fox, B. A., Trong, I. L., Teller, D. C., Okada, T., Stenkamp, R. E., Yamamoto, M., and Miyano, M. (2000) Crystal Structure of Rhodopsin: A G Protein-Coupled Receptor, Science 289, 739-745.
2. Ballesteros, J. A., Jensen, A. D., Liapakis, G., Rasmussen, S. G., Shi, L., Gether, U., and Javitch, J. A. (2001) Activation of the β2-adrenergic receptor involves disruption of an ionic lock between the cytoplasmic ends of transmembrane segments 3 and 6, J. Biol. Chem. 276, 29171-29177.
3. Javitch, J. A., Fu, D., Liapakis, G., and Chen, J. (1997) Constitutive Activation of the β2 Adrenergic Receptor Alters the Orientation of Its Sixth Membrane-spanning Segment, J. Biol. Chem. 272, 18546-18549.
4. Gether, U., Lin, S., Ghanouni, P., Ballesteros, J. A., Weinstein, H., and Kobilka, B. K. (1997) Agonists induce conformational changes in transmembrane domains III and VI of the β2 adrenoceptor, EMBO J. 16, 6737-6747.
5. McAllister, S. D., Hurst, D. P., Barnett-Norris, J., Lynch, D., Reggio, P. H., and Abood, M. E. (2004) Structural Mimicry in Class A G Protein-coupled Receptor Rotamer Toggle Switches: The Importance of the F3.36(201)/W6.48(357) Interaction in Cannabinoid CB1 Receptor Activation, J. Biol. Chem. 279, 48024-48037.
6. Janz, J. M., and Farrens, D. L. (2004) Rhodopsin Activation Exposes a Key Hydrophobic Binding Site for the Transducin α-Subunit C Terminus, J. Biol. Chem. 279, 29767-29773.
7. Alewijnse, A. E., Timmerman, H., Jacobs, E. H., Smit, M. J., Roovers, E., Cotecchia, S., and Leurs, R. (2000) The Effect of Mutations in the DRY Motif on the Constitutive Activity and Structural Instability of the Histamine H2 Receptor, Mol. Pharmacol. 57, 890-898.
8. Gether, U., Ballesteros, J. A., Seifert, R., Sanders-Bush, E., Weinstein, H., and Kobilka, B. K. (1997) Structural Instability of a Constitutively Active G Protein-coupled Receptor. Agonist-Independent Activation due to Conformational Flexibility, J. Biol. Chem. 272, 2587-2590.
9. Scheer, A., Fanelli, F., Costa, T., De Benedetti, P. G., and Cotecchia, S. (1996) Constitutively active mutants of the α1B-adrenergic receptor: Role of highly conserved polar amino acids in receptor activation, EMBO J. 15, 3566-3578.
10. Rosenkilde, M. M., Kledal, T. N., and Schwartz, T. W. (2005) High constitutive activity of a virus-encoded 7TM receptor in the absence of the conserved DRY-motif (Asp-Arg-Tyr) in transmembrane helix 3, Mol. Pharmacol. 68, 11-19.
11. Wilson, R. I., and Nicoll, R. A. (2002) Endocannabinoid signaling in the brain, Science 296, 678-682.
12. Bouaboula, M., Perrachon, S., Milligan, L., Canat, X., Rinaldi-Carmona, M., Portier, M., Barth, F., Calandra, B., Pecceu, F., Lupker, J., Maffrand, J.-P., Le Fur, G., and Casellas, P. (1997) A Selective Inverse Agonist for Central Cannabinoid Receptor Inhibits Mitogen-activated Protein Kinase Activation Stimulated by Insulin or Insulin-like Growth Factor 1. Evidence for a New Model of Receptor/Ligand Interactions, J. Biol. Chem. 272, 22330-22339.
13. 2+ Currents by Reversal of Tonic CB1 Cannabinoid Receptor Activity, Mol. Pharmacol. 54, 1064-1072.
14. Leterrier, C., Bonnard, D., Carrel, D., Rossier, J., and Lenkei, Z. (2004) Constitutive Endocytic Cycle of the CB1 Cannabinoid Receptor, J. Biol. Chem. 279, 36013-36021.
15. Marion, S., Weiner, D. M., and Caron, M. G. (2004) RNA Editing Induces Variation in Desensitization and Trafficking of 5-Hydroxytryptamine 2c Receptor Isoforms, J. Biol. Chem. 279, 2945-2954.
16. Miserey-Lenkei, S., Parnot, C., Bardin, S., Corvol, P., and Clauser, E. (2002) Constitutive Internalization of Constitutively Active Angiotensin II AT1A Receptor Mutants Is Blocked by Inverse Agonists, J. Biol. Chem. 277, 5891-5901.
17. Glass, M., and Felder, C. C. (1997) Concurrent stimulation of Cannabinoid CB1 and dopamine D2 receptors augments cAMP accumulation in striatal neurons: Evidence for a Gs linkage to the CB1 receptor, J. Neurosci. 17, 5327-5333.
18. Glass, M., and Northup, J. K. (1999) Agonist Selective Regulation of G Proteins by Cannabinoid CB1 and CB2 Receptors, Mol. Pharmacol. 56, 1362-1369.
19. Mukhopadhyay, S., and Howlett, A. C. (2005) Chemically Distinct Ligands Promote Differential CB1 Cannabinoid Receptor-Gi Protein Interactions, Mol. Pharmacol. 67, 2016-2024.
20. Yanovski, S. Z. (2005) Pharmacotherapy for Obesity: Promise and Uncertainty, N. Engl. J. Med. 353, 2187-2189.
21. Le Foll, B., and Goldberg, S. R. (2005) Cannabinoid CB1 Receptor Antagonists as Promising New Medications for Drug Dependence, J. Pharmacol. Exp. Ther. 312, 875-883.
22. Reggio, P. (2003) Pharmacophores for ligand recognition and activation/inactivation of the Cannabinoid receptors, Curr. Pharm. Des. 9, 1607-1633.
23. Fay, J. F., Dunham, T. D., and Farrens, D. L. (2005) Cysteine Residues in the Human Cannabinoid Receptor: Only C257 and C264 Are Required for a Functional Receptor, and Steric Bulk at C386 Impairs Antagonist SR141716A Binding, Biochemistry 44, 8757-8769.
24. Ballesteros, J. H., and Weinstein, H. W. (1995) Integrated Methods for the Construction of Three-Dimensional Models and Computational Probing of Structure-Function Relations in G-Protein Coupled Receptors, Methods Neurosci. 25, 366-428.
25. Samama, P., Cotecchia, S., Costa, T., and Lefkowitz, R. J. (1993) A mutation-induced activated state of the β2-adrenergic receptor. Extending the ternary complex model, J. Biol. Chem. 268, 4625-4636.
26. Chin, C. N., Lucas-Lenard, J., Abadji, V., and Kendall, D. A. (1998) Ligand binding and modulation of cyclic AMP levels depend on the chemical nature of residue 192 of the human Cannabinoid receptor 1, J. Neurochem. 70, 366-373.
27. Okada, A., Lansford, R., Weimann, J. M., Fraser, S. E., and McConnell, S. K. (1999) Imaging Cells in the Developing Nervous System with Retrovirus Expressing Modified Green Fluorescent Protein, Exp. Neurol. 156, 394-406.
28. Murphy, J. W., and Kendall, D. A. (2003) Integrity of extracellular loop 1 of the human cannabinoid receptor 1 is critical for high-affinity binding of the ligand CP 55,940 but not SR 141716A, Biochem. Pharmacol. 65, 1623-1631.
29. Abadji, V., Lucas-Lenard, J. M., Chin, C., and Kendall, D. A. (1999) Involvement of the carboxyl terminus of the third intracellular loop of the cannabinoid CB1 receptor in constitutive activation of Gs, J. Neurochem. 72, 2032-2038.
30. Bradford, M. M. (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding, Anal. Biochem. 72, 248-254.
31. Lin, S., Khanolkar, A. D., Fan, P., Goutopoulos, A., Qin, C., Papahadjis, D., and Makriyannis, A. (1998) Novel analogues of arachidonylethanolamide (anandamide): Affinities for the CB1 and CB2 cannabinoid receptors and metabolic stability, J. Med. Chem. 41, 5353-5361.
32. Chin, C. N., Murphy, J. W., Huffman, J. W., and Kendall, D. A. (1999) The third transmembrane helix of the cannabinoid receptor plays a role in the selectivity of aminoalkylindoles for CB2, peripheral cannabinoid receptor, J. Pharmacol. Exp. Ther. 291, 837-844.
33. Kearn, C. S., Blake-Palmer, K., Daniel, E., Mackie, K., and Glass, M. (2005) Concurrent Stimulation of Cannabinoid CB1 and Dopamine D2 Receptors Enhances Heterodimer Formation: A Mechanism for Receptor Cross-Talk? Mol. Pharmacol. 67, 1697-1704.
34. 50) of an enzymatic reaction, Biochem. Pharmacol. 22, 3099-3108.
35. Howlett, A. C., Barth, F., Bonner, T. I., Cabral, G., Casellas, P., Devane, W. A., Felder, C. C., Herkenham, M., Mackie, K., Martin, B. R., Mechoulam, R., and Pertwee, R. G. (2002) International Union of Pharmacology. XXVII. Classification of Cannabinoid Receptors, Pharmacol. Rev. 54, 161-202.
36. Zuscik, M. J., Porter, J. E., Gaivin, R., and Perez, D. M. (1998) Identification of a Conserved Switch Residue Responsible for Selective Constitutive Activation of the β2-Adrenergic Receptor, J. Biol. Chem. 273, 3401-3407.
37. Scheer, A., Costa, T., Fanelli, F., De Benedetti, P. G., Mhaouty-Kodja, S., Abuin, L., Nenniger-Tosato, M., and Cotecchia, S. (2000) Mutational Analysis of the Highly Conserved Arginine within the Glu/Asp-Arg-Tyr Motif of the α1b-Adrenergic Receptor: Effects on Receptor Isomerization and Activation, Mol. Pharmacol. 57, 219-231.
38. 2B-adrenoceptor, Biochem. Biophys. Res. Commun. 306, 959-965.
39. Gifford, A. N., Bruneus, M., Gatley, S. J., and Volkow, N. D. (2000) Cannabinoid receptor-mediated inhibition of acetylcholine release from hippocampal and cortical synaptosomes, Br. J. Pharmacol. 131, 645-650.
40. Cosenza, M., Gifford, A. N., Gatley, S. J., Pyatt, B., Liu, Q., Makriyannis, A., and Volkow, N. D. (2000) Locomotor activity and occupancy of brain cannabinoid CB1 receptors by the antagonist/inverse agonist AM281, Synapse 38, 477-482.
41. Izzo, A. A., Mascolo, N., Tonini, M., and Capasso, F. (2000) Modulation of peristalsis by cannabinoid CB1 ligands in the isolated guinea-pig ileum, Br. J. Pharmacol. 129, 984-990.
42. Hajos, N., and Freund, T. F. (2002) Pharmacological separation of cannabinoid sensitive receptors on hippocampal excitatory and inhibitory fibers, Neuropharmacology 43, 503-510.
43. Barker, E., Westphal, R., Schmidt, D., and Sanders-Bush, E. (1994) Constitutively active 5-hydroxytryptamine2C receptors reveal novel inverse agonist activity of receptor ligands, J. Biol. Chem. 269, 11687-11690.
44. Ehlert, F., and Rathbun, B. (1990) Signaling through the muscarinic receptor-adenylate cyclase system of the heart is buffered against GTP over a range of concentrations, Mol. Pharmacol. 38, 148-158.
45. Capra, V., Veltri, A. F., Foglia, C., Crimaldi, L., Habib, A., Parenti, M., and Rovati, G. (2004) Mutational Analysis of the Highly Conserved ERY Motif of the Thromboxane A2 Receptor: Alternative Role in GPCR Signaling, Mol. Pharmacol. 66, 880-889.
46. Wilbanks, A. M., Laporte, S. A., Bohn, L. M., Barak, L. S., and Caron, M. G. (2002) Apparent loss-of-function mutant GPCRs revealed as constitutively desensitized receptors, Biochemistry 41, 11981-11989.
47. Sealfon, S. C., Chi, L., Ebersole, B. J., Rodic, V., Zhang, D., Ballesteros, J. A., and Weinstein, H. (1995) Related Contribution of Specific Helix 2 and 7 Residues to Conformational Activation of the Serotonin 5-HT Receptor, J. Biol. Chem. 270, 16683-16688.
48. Wilson, M. H., and Limbird, L. E. (2000) Mechanisms Regulating the Cell Surface Residence Time of the Adrenergic Receptor, Biochemistry 39, 693-700.
49. Li, J., Chen, C., Huang, P., and Liu-Chen, L.-Y. (2001) Inverse Agonist Up-Regulates the Constitutively Active D3.49(164)Q Mutant of the Rat Opioid Receptor by Stabilizing the Structure and Blocking Constitutive Internalization and Down-Regulation, Mol. Pharmacol. 60, 1064-1075.
50. Coutts, A. A., Anavi-Goffer, S., Ross, R. A., MacEwan, D. J., Mackie, K., Pertwee, R. G., and Irving, A. J. (2001) Agonist-Induced Internalization and Trafficking of Cannabinoid CB1 Receptors in Hippocampal Neurons, J. Neurosci. 21, 2425-2433.
51. Sheikh, S. P., Vilardarga, J. P., Baranski, T. J., Lichtarge, O., Iiri, T., Meng, E. C., Nissenson, R. A., and Bourne, H. R. (1999) Similar structures and shared switch mechanisms of the β2-adrenoceptor and the parathyroid hormone receptor. Zn(II) bridges between helices III and VI block activation, J. Biol. Chem. 274, 17033-17041.
52. Arnis, S., Fahmy, K., Hofmann, K., and Sakmar, T. (1994) A conserved carboxylic acid group mediates light-dependent proton uptake and signaling by rhodopsin, J. Biol. Chem. 269, 23879-23881.
53. Favre, N., Fanelli, F., Missotten, M., Nichols, A., Wilson, J., diTiani, M., Rommel, C., and Scheer, A. (2005) The DRY Motif as a Molecular Switch of the Human Oxytocin Receptor, Biochemistry 44, 9990-10008.
54. Shapiro, D. A., Kristiansen, K., Weiner, D. M., Kroeze, W. K., and Roth, B. L. (2002) Evidence for a Model of Agonist-induced Activation of 5-Hydroxytryptamine 2A Serotonin Receptors That Involves the Disruption of a Strong Ionic Interaction between Helices 3 and 6, J. Biol. Chem. 277, 11441-11449.
55. Zhou, W., Flanagan, C., Ballesteros, J., Konvicka, K., Davidson, J., Weinstein, H., Millar, R., and Sealfon, S. (1994) A reciprocal mutation supports helix 2 and helix 7 proximity in the gonadotropin-releasing hormone receptor, Mol. Pharmacol. 45, 165-170.
56. Min, K., Zvyaga, T., Cypess, A., and Sakmar, T. (1993) Characterization of mutant rhodopsins responsible for autosomal dominant retinitis pigmentosa. Mutations on the cytoplasmic surface affect transducin activation, J. Biol. Chem. 268, 9400-9404.
57. Farrens, D. L., Altenbach, C., Yang, K., Hubbell, W. L., and Khorana, H. G. (1996) Requirement of Rigid-Body Motion of Transmembrane Helices for Light Activation of Rhodopsin, Science 274, 768-770.
58. Ballesteros, J., Kitanovic, S., Guarnieri, F., Davies, P., Fromme, B. J., Konvicka, K., Chi, L., Millar, R. P., Davidson, J. S., Weinstein, H., and Sealfon, S. C. (1998) Functional microdomains in G-protein-coupled receptors. The conserved arginine-cage motif in the gonadotropin-releasing hormone receptor, J. Biol. Chem. 273, 10445-10453.
59. Feng, W., and Song, Z. H. (2003) Effects of D3.49A, R3.50A, and A6.34E mutations on ligand binding and activation of the cannabinoid-2 (CB2) receptor, Biochem. Pharmacol. 65, 1077-1085.
60. Rhee, M.-H., Nevo, I., Levy, R., and Vogel, Z. (2000) Role of the highly conserved Asp-Arg-Tyr motif in signal transduction of the CB2 cannabinoid receptor, FEBS Lett. 466, 300-304.
61. Liu, W., Eilers, M., Patel, A. B., and Smith, S. O. (2004) Helix Packing Moments Reveal Diversity and Conservation in Membrane Protein Structure, J. Mol. Biol. 337, 713-729.
62. Adamian, L., and Liang, J. (2001) Helix-helix packing and interfacial pairwise interactions of residues in membrane proteins, J. Mol. Biol. 311, 891-907.
63. Hoare, S. R. J., Gardella, T. J., and Usdin, T. B. (2001) Evaluating the Signal Transduction Mechanism of the Parathyroid Hormone 1 Receptor. Effects of Receptor-G-Protein Interaction on the Ligand Binding Mechanism and Receptor Conformation, J. Biol. Chem. 276, 7741-7753.
64. 1 receptor constitutes an agonist/inverse agonist binding region, J. Med. Chem. 46, 5139-5152.
65. Kearn, C. S., Greenberg, M. J., DiCamelli, R., Kurzawa, K., and Hillard, C. J. (1999) Relationships Between Ligand Affinities for the Cerebellar Cannabinoid Receptor CB1 and the Induction of GDP/GTP Exchange, J. Neurochem. 72, 2379-2387.
66. Hurst, D. P., Lynch, D. L., Barnett-Norris, J., Hyatt, S. M., Seltzman, H. H., Zhong, M., Song, Z.-H., Nie, J., Lewis, D., and Reggio, P. H. (2002) N-(Piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H- pyrazole-3-carboxamide(SR141716A) Interaction with Lys 3.28(192) Is Crucial for Its Inverse Agonism at the Cannabinoid CB1 Receptor, Mol. Pharmacol. 62, 1274-1287.
67. Cohen, C., Kodas, E., and Griebel, G. (2005) CB1 receptor antagonists for the treatment of nicotine addiction, Pharmacol. Biochem. Behav. 81, 387-395.
68. Witkin, J. M., Tzavara, E. T., Davis, R. J., Li, X., and Nomikos, G. G. (2005) A therapeutic role for cannabinoid CB1 receptor antagonists in major depressive disorders, Trends Pharmacol. Sci. 26, 609-617.
69. Gary-Bobo, M., Elachouri, G., Scatton, B., Le Fur, G., Oury-Donat, F., and Bensaid, M. (2005) The cannabinoid CB1 receptor antagonist rimonabant (SR141716) inhibits cell proliferation and increases markers of adipocyte maturation in cultured mouse 3T3 F442A preadipocytes, Mol. Pharmacol. 69, 471-478.
70. Horn, F., Bettler, E., Oliveira, L., Campagne, F., Cohen, F. E., and Vriend, G. (2003) GPCRDB information system for G protein-coupled receptors, Nucleic Acids Res. 31, 294-297.
71. Shire, D., Calandra, B., Delpech, M., Dumont, X., Kaghad, M., Le Fur, G., Caput, D., and Ferrara, P. (1996) Structural Features of the Central Cannabinoid CB1 Receptor Involved in the Binding of the Specific CB1 Antagonist SR 141716A, J. Biol. Chem. 271, 6941-6946.